🇺🇸 ImmunityBio, Inc.IBRX

Investor Event Form 8-K 09-11-2026 06:33:23 EST

Subject: 8-K Items 7.01, 9.01

Overview: ANKTIVA plus BCG met the primary efficacy endpoint in the QUILT-2.005 trial for BCG-naïve NMIBC, with a supplemental BLA submission planned by year-end 2026.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest